Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. (PCSA): 7 pipeline candidates · ~2 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
1.5 months
D/E 0.78 · 0% dilution
Lead: Phase 2
7 candidates
N/A
31 buys · 0 sells (180d)
A transparent, data-derived signal for Processa Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.9M
Cash
$1.7M
Quarterly Burn
$3.6M
Runway
1.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$333K
| Holder | Shares | Value |
|---|---|---|
| connective capital management, llc | 70,736 | $179K |
| vanguard capital management llc | 25,458 | $64K |
| geode capital management, llc | 24,908 | $63K |
| vanguard fiduciary trust co | 10,857 | $27K |
| citigroup inc | 14 | $35 |
| jones financial companies lllp | 7 | $17 |
| wells fargo & company/mn | 6 | $15 |
Frequently asked questions
How many drug candidates are in Processa Pharmaceuticals, Inc.'s pipeline?
Processa Pharmaceuticals, Inc. (PCSA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Processa Pharmaceuticals, Inc.'s lead drug candidate?
Processa Pharmaceuticals, Inc.'s most advanced tracked candidate is ngc-cap (Phase 2) for advanced or metastatic breast cancer.
What is Processa Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Processa Pharmaceuticals, Inc. has approximately 1.5 months of cash runway.
What is Processa Pharmaceuticals, Inc.'s market capitalization?
Processa Pharmaceuticals, Inc.'s market capitalization is approximately $5.9M.
Who is the CEO of Processa Pharmaceuticals, Inc.?
Mr. George K. Ng Esq., J.D. is the chief executive officer of Processa Pharmaceuticals, Inc. (PCSA).
Get the full picture on Processa Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.